Focus: Aurinia is a specialty pharmaceutical company focused on small molecules for immunology and nephrology, with a single approved product generating 100% of revenue. Based in Edmonton, Canada, the company operates at a mid-cap biotech scale with concentrated commercial risk.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Aurinia Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Aurinia Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Aurinia Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Sole approved product driving 100% of company revenue; patent-protected until 2037 provides long-term exclusivity runway.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: state DOL filings, aggregated via Big Local News
No visible FDA enforcement actions, shortages, or WARN Act filings indicate regulatory and operational stability, but absence of public data on recent personnel decisions limits assessment.
+2 more